AB0200 COMPARISON OF TREATMENT AND DISEASE ACTIVITY OF BETWEEN EORA AND YORA PATIENTS IN A NATIONWIDE DATABASE OF RHEUMATOID ARTHRITIS IN JAPAN “NINJA”

Background Elderly-onset rheumatoid arthritis (EORA) has different characteristics from younger-onset RA (YORA), however, few reports have conducted large-scale and long-term comparisons of treatment disease activity between EORA YORA. Objectives To compare the changes in YORA patients to examine who achieved remission them using data a real-world database Japan. Methods Analysis was performed 2010, 2013, 2016, 2019 National Database Rheumatic Diseases Japan (NinJa). Patients were grouped according age onset into G1: <65 years (divided G1a G1b ≧65 by at analysis), G2: 65-74 years, G3:≧75 years. Results MTX usage rate decreased over time G2 (58.3% 2013→55.1% 2016→54.4% 2019) G3 group (41.1→39.5→37.9%). Biologics/JAKi increased (G1b:24.4→28.2→ 33.3%, G2:19.1→20.3→23.7%, G3:12.3→14.5→19.1%) steroid (G1b:49.1→41.8→35.1%, G2:42.2→36.8→29.5%, G3:50.9→45.9→39.2%) all groups. TNFi (G1b:19.5→18.0→17.3%, G2:15.4→ 14.1→12.7%, G3:6.2→4.3→5.1%) but IL-6i (G1b:5.2→7.4→9.5%, G2:4.1→4.3→5.9%, G3:2.7→3.4→3.3%) except for group. CTLA-4Ig also (G1b:3.7→5.3→6.7%, G2:2.7→5.5→5.9%, G3:3.6→6.5→8.1%) The SDAI groups (G1a:34.4→41.2→44.6%, G1b:25.1→31.4→35.2%, G2:33.1→37.1→42.2%, G3:30.0→35.9→39.3%) showed similar with In analysis stratified NinJa 2019, positive RF ACPA (ex RF. G3: 71.0→64.5→53.2%, ACPA. 66.4→56.2→46.5%) proportion male 23.0→30.3→35.1%) as (moderate / high → low remission) Also, two or more DMARDs 43.8→35.2→22.4%) G3:52.5→37.9→30.2%). Furthermore, comparison each group, (G1b:62.9→G2:61.7→G3:40.9%) biologics/JAKi (32.5→23.6→15.3%) increased, (20.3→20.6→30.2%). Conclusion Disease improved time, regardless onset. same achievement YORA, content those differed greatly depending on Disclosure Interests Toshihiro Matsui Speakers bureau: Abbvie, Asahi Kasei, Ono, Chugai, Eli lilly, Pfizer, Grant/research support from: Shigeto Tohma: None declared